Orphan drugs and the principles of their marketing authorization procedures and clinical use
One of the most complicated issues of modern medicine is diagnosis, treatment and prevention of rare diseases. In the structure of rare diseases the vast majority accounts for genetically determined disorders. The introduction of genetic testing methods helped to identify a lot of hereditary disease...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2018-02-01
|
| Series: | Биопрепараты: Профилактика, диагностика, лечение |
| Subjects: | |
| Online Access: | https://www.biopreparations.ru/jour/article/view/16 |
| _version_ | 1797244561385324544 |
|---|---|
| author | A. A. Soldatov Zh. I. Avdeeva N. A. Alpatova N. V. Medunitsyn S. L. Lysikova |
| author_facet | A. A. Soldatov Zh. I. Avdeeva N. A. Alpatova N. V. Medunitsyn S. L. Lysikova |
| author_sort | A. A. Soldatov |
| collection | DOAJ |
| description | One of the most complicated issues of modern medicine is diagnosis, treatment and prevention of rare diseases. In the structure of rare diseases the vast majority accounts for genetically determined disorders. The introduction of genetic testing methods helped to identify a lot of hereditary diseases, that currently reach the number of 8,000 cases and according to estimations the frequency of their detection is about to increase. Medicinal products for diagnosis or treatment of rare diseases form the group of orphan drugs. Biologicals are the most effective medicinal products in the whole group, due to their ability to bind specifically with the «target receptor», which allows to use them as targeted drugs. Another advantage of biologicals, compared with preparations of chemical origin, is their low toxicity. Orphan drug provision is the most severe issue because the treatment of severe forms of rare diseases may require the prescription of an expensive drug. Manufacturing of orphan drugs may be unprofitable for the reason of the low prevalence of rare diseases. Therefore, the availability of orphan drugs for patients depends on the amount of state participation in manufacture stimulation. In various countries regulatory requirements for the recognition of a disease as a rare disease, and marketing authorization procedures for orphan drugs are developed with due regard to the social and economic characteristics of the country. The article presents the analysis of the regulatory requirements for various countries for the detection of rare diseases, and a common approach to marketing authorization procedure for the drugs used in treatment of rare diseases, exemplified by biological orphan preparations. |
| first_indexed | 2024-03-08T21:44:01Z |
| format | Article |
| id | doaj.art-529672b09bd64b58911646911672a181 |
| institution | Directory Open Access Journal |
| issn | 2221-996X 2619-1156 |
| language | Russian |
| last_indexed | 2024-04-24T19:12:58Z |
| publishDate | 2018-02-01 |
| publisher | Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Биопрепараты: Профилактика, диагностика, лечение |
| spelling | doaj.art-529672b09bd64b58911646911672a1812024-03-26T09:10:51ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562018-02-010341616Orphan drugs and the principles of their marketing authorization procedures and clinical useA. A. Soldatov0Zh. I. Avdeeva1N. A. Alpatova2N. V. Medunitsyn3S. L. Lysikova4Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииOne of the most complicated issues of modern medicine is diagnosis, treatment and prevention of rare diseases. In the structure of rare diseases the vast majority accounts for genetically determined disorders. The introduction of genetic testing methods helped to identify a lot of hereditary diseases, that currently reach the number of 8,000 cases and according to estimations the frequency of their detection is about to increase. Medicinal products for diagnosis or treatment of rare diseases form the group of orphan drugs. Biologicals are the most effective medicinal products in the whole group, due to their ability to bind specifically with the «target receptor», which allows to use them as targeted drugs. Another advantage of biologicals, compared with preparations of chemical origin, is their low toxicity. Orphan drug provision is the most severe issue because the treatment of severe forms of rare diseases may require the prescription of an expensive drug. Manufacturing of orphan drugs may be unprofitable for the reason of the low prevalence of rare diseases. Therefore, the availability of orphan drugs for patients depends on the amount of state participation in manufacture stimulation. In various countries regulatory requirements for the recognition of a disease as a rare disease, and marketing authorization procedures for orphan drugs are developed with due regard to the social and economic characteristics of the country. The article presents the analysis of the regulatory requirements for various countries for the detection of rare diseases, and a common approach to marketing authorization procedure for the drugs used in treatment of rare diseases, exemplified by biological orphan preparations.https://www.biopreparations.ru/jour/article/view/16орфанные препаратыбиологические препаратыредкие заболеванияраспространенность редких заболеванийлечение редких заболеванийorphan drugsbiological preparationsrare diseasesprevalence of rare diseasestreatment of rare diseases |
| spellingShingle | A. A. Soldatov Zh. I. Avdeeva N. A. Alpatova N. V. Medunitsyn S. L. Lysikova Orphan drugs and the principles of their marketing authorization procedures and clinical use Биопрепараты: Профилактика, диагностика, лечение орфанные препараты биологические препараты редкие заболевания распространенность редких заболеваний лечение редких заболеваний orphan drugs biological preparations rare diseases prevalence of rare diseases treatment of rare diseases |
| title | Orphan drugs and the principles of their marketing authorization procedures and clinical use |
| title_full | Orphan drugs and the principles of their marketing authorization procedures and clinical use |
| title_fullStr | Orphan drugs and the principles of their marketing authorization procedures and clinical use |
| title_full_unstemmed | Orphan drugs and the principles of their marketing authorization procedures and clinical use |
| title_short | Orphan drugs and the principles of their marketing authorization procedures and clinical use |
| title_sort | orphan drugs and the principles of their marketing authorization procedures and clinical use |
| topic | орфанные препараты биологические препараты редкие заболевания распространенность редких заболеваний лечение редких заболеваний orphan drugs biological preparations rare diseases prevalence of rare diseases treatment of rare diseases |
| url | https://www.biopreparations.ru/jour/article/view/16 |
| work_keys_str_mv | AT aasoldatov orphandrugsandtheprinciplesoftheirmarketingauthorizationproceduresandclinicaluse AT zhiavdeeva orphandrugsandtheprinciplesoftheirmarketingauthorizationproceduresandclinicaluse AT naalpatova orphandrugsandtheprinciplesoftheirmarketingauthorizationproceduresandclinicaluse AT nvmedunitsyn orphandrugsandtheprinciplesoftheirmarketingauthorizationproceduresandclinicaluse AT sllysikova orphandrugsandtheprinciplesoftheirmarketingauthorizationproceduresandclinicaluse |